Further evidence of favorable effects of gemfibrozil on the lipid profile in renal allograft recipients

Nephron

Volumn 73, Issue 3, 1996, Pages 491-492

  Ok, Ercan ^a   Kursat, Seyhun ^a   Alev, Mete ^a   Tobu, Mahmut ^a   Tokat, Yaman ^a   Akcicek, Fehmi ^a   Hoscoskun, Cüneyt ^a   Basci, Ali ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; GEMFIBROZIL; LIPID;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERLIPIDEMIA; KIDNEY ALLOGRAFT; LETTER; MALE; PRIORITY JOURNAL;

ADULT; ANTILIPEMIC AGENTS; FEMALE; GEMFIBROZIL; HUMANS; KIDNEY TRANSPLANTATION; LIPIDS; MALE;

EID: 0029899488     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000189121     Document Type: Article

References (8)

1. Lowrie EG, Lazans JM. Mocelin AJ: Survival of patients undergoing chronic hemodialysis and renal transplantation. N Engl J Med 1973; 288:863-867.
2. Disler PB. Goldberg RB. Kuhn L: The role of diet in the pathogenesis and control of hypcr-lipidemia after renal transplantation. Clin Nephrol 1981;16:29-34.
3. Keogh A, Doy R. Critchely L: The effect of food and cholestyramine on the absorption of cardiac transplant recipients. Transplant Proc 1988;20:27-30.
4. Corpicr JL, Jones PH. Suki WN: Rhabdomvo-lysis and renal injury with lovastatin use. JAMA 1988;260:239-241.
5. Knight RI, Vathsala A, Schoenberg L: Treatment of hvpcrlipidemia in renal transplant patients with gemfibrozil and dietary modification. Transplantation 1992;53:224-225.
6. Grundy SM. Vega L: Fibric acids: Effects on lipids and lipoprotein metabolism. Am J Med 1987;83:9-20.
7. Chan TM, Cheng KP, Tam SCF: Hypcrlipid-entia after renal transplantation: Treatment with gemfibrozil. Nephron 1994:67:317-321
8. Carlson LA. Aberg H: Scrum triglycerides: An independent risk factor for myocardial infarction but not for angina pectoris. N Engl J Med 1985:312:1127-1131.